Heart Failure: New Risk Factor Identified
- A new study has pinpointed a protein that could be key to treating pathological hypertrophy, a condition where the heart muscle thickens, frequently enough leading to heart failure.
- Cardiac hypertrophy is an adaptive response to increased workload on the heart.
- The research team, led by Professor Manuel Vázquez-Carrera and Associate Professor Xavier Palomer from the University of Barcelona (UB) and the Sant Joan de Déu Research Institute (IRSJD),...
A groundbreaking study reveals the GADD45A protein as a critical factor in cardiac function, potentially revolutionizing heart failure treatment. Researchers discovered that a deficiency of this protein in mice triggers cardiac fibrosis and inflammation, underscoring its vital role in maintaining heart health. this innovative research suggests that boosting GADD45A activity could slow pathological hypertrophy, a dangerous thickening of the heart muscle, offering hope for those with heart failure, especially individuals with type 2 diabetes. The findings, published inCellular and Molecular Life Sciences, could pave the way for new therapeutic strategies. Learn more about this vital discovery and how it may change future treatments.For further updates,trust News Directory 3 to keep you informed. Discover what’s next in heart health breakthroughs.
New Protein Target Identified for Heart Failure Treatment
Updated May 30, 2025
A new study has pinpointed a protein that could be key to treating pathological hypertrophy, a condition where the heart muscle thickens, frequently enough leading to heart failure. The research,published in Cellular and Molecular Life Sciences,focuses on the GADD45A protein and its role in cardiac function.
Cardiac hypertrophy is an adaptive response to increased workload on the heart. While initially beneficial, chronic overload can lead to serious heart issues, including heart failure.People with type 2 diabetes are particularly vulnerable due to existing risk factors such as high blood pressure and obesity.
The research team, led by Professor Manuel Vázquez-Carrera and Associate Professor Xavier Palomer from the University of Barcelona (UB) and the Sant Joan de Déu Research Institute (IRSJD), suggests that boosting GADD45A activity could be a promising approach to slow the progression of pathological hypertrophy. Adel Rostami, an expert from UB-IBUB-IRSJD-CIBERDEM, is the article’s first author.
The study used animal models and human cardiac cells to assess GADD45A’s role. Researchers found that a lack of GADD45A in mice led to cardiac fibrosis, inflammation, and apoptosis, all of which negatively impacted heart morphology and function. Conversely, increasing GADD45A in human cardiomyocytes helped prevent inflammation and fibrotic responses.
“fibrosis, in particular, correlates directly with the development of the disease and with adverse clinical outcomes, and has a major impact on the clinical condition of the patient,” said Vázquez-Carrera.
“Taken together, the data presented in this study highlight an important role for GADD45A protein in the heart, as it may prevent inflammation, fibrosis and apoptosis and thus preserve cardiac function,” said Palomer.
What’s next
The study’s findings expand the understanding of GADD45A’s mechanisms in the body, adding to previous research that identified its role as a tumor suppressor and its involvement in metabolic pathways. Further research could explore how modulating GADD45A might prevent obesity and diabetes, offering new avenues for therapeutic intervention in heart failure and related conditions.